Get the Stockscreener App
0.05
0.00%
0.00
Telesis Bio Inc stock is traded at $0.05, with a volume of 195.
It is up +0.00% in the last 24 hours and down -28.17% over the past month.
See More
Previous Close:
$0.05
Open:
$0.05
24h Volume:
195
Relative Volume:
0.88
Market Cap:
$N/A
Revenue:
$30.00M
Net Income/Loss:
$-38.17M
P/E Ratio:
-0.0385
EPS:
-1.3
Net Cash Flow:
$-35.49M
1W Performance:
+53.28%
1M Performance:
-28.17%
6M Performance:
-69.27%
1Y Performance:
-85.40%
1-Day Range:
$0.05
$0.05
1-Week Range:
$0.05
$0.1956
52-Week Range:
$0.05
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
Compare TBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.05 | 0 | 30.00M | -38.17M | -35.49M | -1.30 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-18-21 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-18-21 | Downgrade | Truist | Buy → Hold |
| Oct-05-20 | Initiated | Goldman | Buy |
| Jul-07-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-06-20 | Initiated | William Blair | Outperform |
| Jun-26-20 | Initiated | SunTrust | Buy |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jun-18-19 | Initiated | ROTH Capital | Buy |
| Dec-24-18 | Initiated | H.C. Wainwright | Buy |
| Jul-23-18 | Initiated | Citigroup | Buy |
| Jul-23-18 | Initiated | Evercore ISI | Outperform |
| Jul-23-18 | Initiated | Leerink Partners | Outperform |
View All
Telesis Bio Inc Stock (TBIO) Latest News
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities - Yahoo
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Regeneron (REGN) Adopts Telesis Bio's Gene Synthesis Platform | - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency - Yahoo
Regeneron Pharmaceuticals (NasdaqGS:REGN) Adopts Innovative Technology for Faster Drug Discovery - Yahoo Finance
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - BioSpace
TBIOTRANSLATE BIO, INC. Latest Stock News & Market Updates - Stock Titan
Telesis Bio (NASDAQ:TBIO) Stock Price Up 28.9% – Here’s Why - American Banking and Market News
Telesis Bio (NASDAQ:TBIO) Trading Up 28.9% – Still a Buy? - Defense World
TELESIS BIO INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Telesis Bio (NASDAQ:TBIO) Trading Down 23.1% – Here’s Why - Defense World
$21M Investment Powers Telesis Bio's Game-Changing Overnight DNA Synthesis Technology - StockTitan
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Business Wire
Telesis Bio (NASDAQ:TBIO) Trading 27.3% Higher – Should You Buy? - Defense World
Financial Contrast: Telesis Bio (NASDAQ:TBIO) and Prenetics Global (NASDAQ:PRE) - Defense World
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
Telesis Bio (NASDAQ:TBIO) Trading 11.6% Higher – Here’s What Happened - Defense World
Telesis Bio (NASDAQ:TBIO) Shares Down 2.4% – Time to Sell? - Defense World
Telesis Bio (NASDAQ:TBIO) Stock Price Down 9.5% – Should You Sell? - Defense World
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio (NASDAQ:TBIO) Shares Down 2.7% – What’s Next? - Defense World
Telesis Bio, Inc. announced that it has received $3 million in funding - Marketscreener.com
Telesis Bio (NASDAQ:TBIO) Shares Up 15.5% – Time to Buy? - Defense World
Telesis Bio secures $3 million in promissory notes - Investing.com
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
Telesis Bio Announces Departure of Chief Legal Officer - TipRanks
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62% - MSN
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - MSN
Telesis Bio stock gains on Danaher deal (NASDAQ:TBIO) - Seeking Alpha
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Dow Tumbles 350 Points; US Inflation Rate Slows In August - Benzinga
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market | TBIO Stock News - Stock Titan
Telesis Bio Names CEO Eric Esser as Chair After Five Board Members Resign - MarketWatch
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Enzymatic DNA Synthesis Market Size & Share Report, 2030 - Grand View Research
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results - Yahoo Finance
Telesis Bio Reports First Quarter 2024 Financial Results - Yahoo Finance
Telesis Bio Announces Reverse Stock Split - Yahoo Finance
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results, Business Wires News - AsiaOne
Why Is Charge Enterprises (CRGE) Stock Down 41% Today? - InvestorPlace
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS - The Korea Bizwire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023, Business Wires News - AsiaOne
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio to Present at Jefferies Healthcare Conference 2023 - Koreabizwire
Sidley Represents Northpond Ventures in Its PIPE Investment in Telesis Bio Inc. - Sidley Austin LLP
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock and Warrants to Purchase an Additional $46.2 Million of Common Stock - Koreabizwire
Telesis Bio to Present at SynBioBeta 2023 - Koreabizwire
Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall - Daily Sentinel Star
Telesis Bio Inc Stock (TBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.38%
Cap:
|
Volume (24h):